Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for brolucizumab

  1. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    31 August 2022
    View recommendations

    Sections for TA820

  2. Brolucizumab for treating wet age-related macular degeneration (TA672)

    Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    3 February 2021
    View recommendations

    Sections for TA672

  3. Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]

    In development [GID-TA11193] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  4. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.